Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Expert Review of Neurotherapeutics is Scopus-indexed (Q1, CiteScore 6.3), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1473-7175Verify ISSN ↗1744-8360Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 61 / 278 | 78th | Q1 |
| Neurology (clinical) | 91 / 403 | 77th | Q1 |
| Neuroscience (all) | 38 / 112 | 66th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2001–present, best quartile Q1, CiteScore 6.3.
Expert Review of Neurotherapeutics is Q1 in Pharmacology (medical) (rank 61 of 278), Q1 in Neurology (clinical) (rank 91 of 403) and Q2 in Neuroscience (all) (rank 38 of 112), by CiteScore 2025.
Expert Review of Neurotherapeutics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.3, which places it in quartile Q1 at the 78th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.106, quartile Q1, with an H-index of 110.
Expert Review of Neurotherapeutics is published by Taylor and Francis Ltd. Its print ISSN is 1473-7175 and its online ISSN is 1744-8360.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Expert Review of Neurotherapeutics has an h-index of 125 and a 2-year mean of 4.24 citations per paper (OpenAlex). Its Scopus CiteScore is 6.3, quartile Q1. On 2-year citations it ranks #41 of 271 Scopus journals in Pharmacology (medical).
Expert Review of Neurotherapeutics published 115 papers in 2025; its busiest recent year was 2020 with 132. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from United States (28.6%), Italy (17.7%) and United Kingdom (6.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.6 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.